FDA Announces Joint Meeting of Drug Safety and Risk Management Advisory Committee and Dermatologic and Ophthalmic Drugs Advisory Committee

Summary

The US Food and Drug Administration (FDA) has scheduled a joint meeting of its Drug Safety and Risk Management Advisory Committee and the Dermatologic and Ophthalmic Drugs Advisory Committee to discuss various topics related to drug safety and risk management, including the review of new drug applications and the evaluation of existing medications.